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Ribosomal Protein L13a as a Reference Gene for Human
Bone Marrow-Derived Mesenchymal Stromal Cells During
Expansion, Adipo-, Chondro-, and Osteogenesis
Deborah Studer, M.Sc.,1,2 Stefanie Lischer, Dipl.-Ing.,1 Wolfram Jochum, Ph.D.,3 Martin Ehrbar, Ph.D.,4
Marcy Zenobi-Wong, Ph.D.,2 and Katharina Maniura-Weber, Ph.D.1
In the field of human mesenchymal stromal cell (MSC) research, quantitative real-time reverse transcription–
polymerase chain reaction (qPCR) is the method of choice to study changes in gene expression patterns upon
differentiation, application of stimuli, or of factors such as inhibitors or siRNAs. To reliably detect small changes,
the use of a reference gene (RG) that is stably expressed under all conditions is essential. The large number of
different RGs used in the field and the lack of validation of their suitability make the comparison between studies
impossible. Therefore, this work aims to establish one single RG for mesodermal differentiation studies that use
MSCs. Seven commonly used RGs (glyceraldehyde-3-phosphate dehydrogenase [GAPDH], ribosomal protein L13a
[RPL13a], beta-actin [ACTB], tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta-
polypeptide [YWHAZ], eukaryotic translational elongation factor 1 alpha [EF1a], b2-microglobulin [B2M], and 18S
ribosomal RNA [18S]) were investigated concerning their mRNA expression stability during expansion of bone
marrow-derived MSCs up to four passages as well as during their adipo-, chondro-, and osteogenenic differen-
tiation on days 9, 16, and 22 after induction. RPL13a was validated for qPCR studies of MSCs (bone marrow- and
placenta-derived) and, additionally, for primary human bone cells (HBCs) and the osteosarcoma cell line MG-63.
GAPDH and ACTB, the two most frequently used RGs, showed the highest expression variance. The superior
performance of RPL13a should make it the RG of choice for all MSC studies addressing mesodermal differentiation.
Introduction
The growing field of research on mesenchymal stromalcells (MSCs) for tissue regeneration and tissue engi-
neering1–4 highly depends on reliable, fast, and sensi-
tive methods to accurately detect small changes in gene
expression during expansion, differentiation, or redif-
ferentiation. Quantitative real-time reverse transcription–
polymerase chain reaction (termed qPCR according to MIQE
guidelines5) is the most popular method owing to its ease of
use and high sensitivity so that it can be performed with a
small number of cells. qPCR as a quantitative analysis
method greatly depends on an appropriate internal data
normalization.6–9 At the moment, the so-called reference
genes (RGs) are the gold standard to correct for the amount
of starting material, sample-to-sample variations, and am-
plification efficiencies.7,9,10 Such RGs should show a constant
expression in different tissues or cells under all experimental
conditions. Candidate normalization genes are therefore
constitutive genes, which are constantly expressed at abun-
dant levels in cells under different conditions, generally in-
volved in basic cellular functions. A vast number of
possible RGs are used in current research; however, thor-
ough validation of their presumed stability in mRNA ex-
pression is mostly lacking. Several studies have shown that
the expression level of frequently used control genes in MSC
studies, such as glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and beta actin (ACTB), is notably unstable be-
tween different donors,11 differentiation,12,13 and cell ex-
pansion conditions.12 Although Quiroz et al.13 conducted a
study comparing GAPDH, ribosomal protein L13a (RPL13a),
and ACTB for normalization of osteogenic differentiation of
MSCs, there are, to our knowledge, no comprehensive
studies investigating the gene expression stability of a broad
range of RG over all three mesodermal differentiation line-
ages: bone, cartilage, and adipose tissue.
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In this study, we aim to establish one single RG for all
three mesodermal differentiation lineages in human bone
marrow-derived MSCs (hBM-MSCs) as well as other human
MSCs and bone progenitor cells. Seven commonly used
RGs (18S ribosomal RNA, b2-microglobulin B2M, eukaryotic
translational elongation factor 1 alpha EF1a, ACTB, GAPDH,
RPL13a and tyrosine 3-monooxygenase/tryptophan 5-mono-
oxygenase activation protein, and zeta polypeptide YWHAZ)
were analyzed based on different stability parameters.
Materials and Methods
Cells
hBM-MSCs, primary human bone cells (HBCs), and
human placenta-derived MSCs (hPD-MSCs) were freshly
isolated (see protocols below) and expanded in an MSC-
proliferation medium composed of a minimal essential me-
dium (a-MEM; Invitrogen, #22561) supplemented with 10%
fetal bovine serum (FBS; Lonza), 1% penicillin–streptomy-
cin–neomycin antibiotic mixture (100 · ) (PSN; Gibco),
and 1ng/mL human basic fibroblast growth factor (FGF-2;
Sigma, #F0291) in a humidified incubator at 37C with 5%
CO2 and 95% air. Bone marrow-derived MSCs were also
purchased from Lonza (Lonza MSCs, Lonza, #PT-2501), and
the MG-63 human osteosarcoma cell line was from ATTC
(#CRL-1427). Lonza MSCs were expanded according to
the manufacturer’s protocol, and MG-63 in the MG-63-
proliferation medium comprised the Dulbecco’s modified
Eagle’s medium (DMEM; Gibco, #41965) supplemented with
10% FBS, 1% PSN, 1% l-glutamine (Gibco, #25030, 100· ),
and 1% sodium pyruvate (Gibco, #11360, 100 · ). Cells were
passaged (split ratio 1–5) using trypsin-ethylenediaminete-
traacetic acid (EDTA) (Sigma, #T3924; 1 · ).
Isolation of human primary cells
Isolation of hBM-MSCs. The MSCs were isolated from
femur-derived bone marrow samples that were obtained
during surgical hip replacement of otherwise healthy pa-
tients (two women and one man, age between 44 and 79
years) after having received informed consent. The protocol
was approved by the ethics board of the Kantonspital
St.Gallen, Switzerland (ethics committee approval number
EKSG08/014/1B). The bone marrow samples were incu-
bated in 20mL isolation medium [25mM HEPES (Fluka,
#54459), 128.5mM NaCl (Fluka, #71380), 5.4mM KCl (Fluka,
#60130), 5.5mM d(+ )-glucose (Sigma, #G7528), 51.8mM
d(+ )-saccharose (Sigma, #84097), 0.1% bovine serum albumin
(Sigma, #A6003)] overnight at 4C. Afterwards, the sample
was centrifuged at 110 g for 15min at 4C to remove fat tissue.
The remaining pieces of trabecular bone were rinsed several
times with an isolation medium that was collected and filtered
through a 200-mm filter. The filtered cell solution was centri-
fuged, and the resulting cell pellet resuspended in MSC-
proliferation medium for cell counting (Casy 1 DT; Roche
Innovatis AG) and seeded at a density of 1· 107 cells in a T75
culture flask containing the proliferation medium.
Isolation of HBCs. Primary HBCs were isolated from the
same samples as hBM-MSCs (see above). After the hBM-
MSCs were collected, the pieces of trabecular bone were
further cleaned from remaining tissue and cells under micro-
scopic observation using forceps and thorough rinsing with
isolation medium. Five to 10 pieces of bone (*25mg) were
placed in a T75 flask together with 20mL MSC-proliferation
medium, which was changed for the first time after 1 week
and later biweekly. The bone pieces were left in the culture
flask until the outgrowing cells reached 70% confluency.
Isolation of hPD-MSCs. hPD-MSCs were isolated ac-
cording to Semenov et al.14 following the protocol approved
by the ethics committee of the district of Zurich (study
Stv22/2006). Placentas were collected from two donors im-
mediately after an elective caesarean section and the isolated
cells suspended in a T75 flask containing 15mL MSC-pro-
liferation medium.
Multilineage differentiation assay
Adipogenic differentiation. For adipogenic induction,
MSCs were seeded at an initial density of 26,000 cells/cm2
and were first cultivated in an adipo-maintenance medium
consisting of the a-MEM supplemented with 10% FBS, 1%
PSN, and 10 mg/mL insulin (dissolved in 0.01M HCl [pH 2–
3]; Sigma, #I-6634) for 1 day followed by cultivation in the
adipo-induction medium consisting of the a-MEM supple-
mented with 10% FBS, 1% PSN, 1mM dexamethasone (Sig-
ma, #D-4902), 10 mg/mL insulin, 0.5mM isobutyl-1-
methylxanthine (Sigma, #I-5879), and 200 mM indomethacin
(Sigma, #I-7378) for 3 days. The alteration of those two media
was repeated over the whole cultivation period of 22 days.
Control cultures were performed in the MSC-proliferation
medium (see above).
Chondrogenic differentiation. Chondrogenic differentia-
tion of MSCs was induced by pellet culture for which 250,000
cells were placed in a 15-mL polypropylene tube and centri-
fuged at 250 g for 5min. The pellet was cultured at 37C with
5% CO2 in 500mL of the chondrogenic medium that consisted
of high-glucose DMEM (Gibco, #41965) supplemented with
100ng/mL bone morphogenetic protein 2 (BMP-2; kind gift
from F.Weber, University Hospital Zu¨rich, Switzerland),
10ng/mL transforming growth factor b3 (TGF-b3, Peprotech,
#100-36E), 100 nM dexamethasone, 50mg/mL ascorbate-2-
phosphate (Sigma, #A8960), 40mg/mL proline (Fluka, #81709),
100mg/mL sodium pyruvate (Fluka, #15990), and 1% ITS+
Universal Culture Supplement Premix (6.25mg/mL insulin,
6.25mg/mL transferrin, 6.25ng/mL selenious acid, 1.25mg/
mL serum albumin, and 5.35mg/mL linoleic acid; BD Bios-
ciences, #354352). The mediumwas replaced every 3–4 days for
22 days. As a control, pellets were cultivated in a chondrogenic
medium lacking dexamethasone, BMP-2, and TGF-b3.
Osteogenic differentiation. To induce osteogenic differ-
entiation of MSCs and HBCs, the cells were seeded at an
initial density of 2000 cells/cm2 and cultivated in an a-MEM
supplemented with 10% FBS, 1% PSN, 10 nM dexametha-
sone, 50mM ascorbate-2-phosphate, 2mM b-glyceropho-
sphate (Sigma, #G-9891), and 10 nM 1,25-dihydroxyvitamin
D3 (Sigma, #D-1530). MG-63 cells were osteogenically in-
duced in an MG-63-proliferation medium (composition
see above) further supplemented with 50 nM 1,25-dihy-
droxyvitamin D3, 50 mg/mL ascorbate-2-phosphate, 10 nM
b-glyercolphosphate, and 10 nM dexamethasone. The
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Table 1. Gene Expression Analysis of Key Differentiation Markers
Adipo Chondro Osteo
Donor Passage aP2 PPARg Coll II Aggrecan Coll I Osteocalcin
1 1 635 7 1,452,393 228 6 3
4 167 14 643,985 53 6 6
2 1 809 125 875,653 122 9 44
4 6237 558 374,170 80 4 20
3 1 17,783 48 139,187 12 8 7
4 135,381 14 10,897 13 10 23
Relative expression (2-DDCq) of differentiation markers of all donors at passages 1 and 4 at day 22 of induction of adipogenesis (adipo),
chondrogenesis (chondro), and osteogenesis (osteo). RPL13a used as a normalizer and control culture day 2 as calibrator of all data. aP2, fatty
acid-binding protein 4; PPARg, peroxisome proliferator-activated receptor gamma; Coll II, collagen II; Coll I, collagen I; RPL13a, ribosomal
protein L13a.
FIG. 1. Multilineage differentiation
potential of MSCs. (A) Adipogenic
(ADIPO) cultures stained with Oil Red
O/DAPI. (B) Chondrogenic (CHON-
DRO) pellet culture stained with Al-
cian blue/periodic acid Schiff. Control
day 22 too small for analysis. (C) Os-
teogenic (OSTEO) cultures stained
with collagen I/DAPI at days 9, 16,
and 22 of induction in a differentiation
or control medium. Scale bars = 200
mm. MSCs, mesenchymal stromal cell;
DAPI, 4¢-6-diamidino-2-phenylindole.
Color images available online at
www.liebertpub.com/tec
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differentiation media were replaced every 3–4 days for up to
22 days (for MSCs) or for 7 days (HBCs and MG-63). As a
control condition, cells were cultured in MSC- respectively
MG-63-proliferation medium (composition see above).
RNA isolation and quantification
Cells grown in monolayer were detached using trypsin-
EDTA (Sigma, #T3924, 1 · ) and centrifuged at 250 g for 5min
to form a cell pellet. Cartilage pellets were digested with
3mg/mL collagenase II (Sigma, #C6885) for 2 h to break
down the abundant negatively charged extracellular matrix
and thereby increasing the RNA yield using affinity column-
based extraction. Afterward, the pellet was washed in
phosphate-buffered saline (PBS), and total RNA was pre-
pared using the Qiagen Micro Kit (Qiagen, #74004) according
to the manufacturer’s protocol. All samples were treated
with DNAse I (Qiagen, #79254, 1500 Kunitz units). The RNA
concentration was determined using a Nanodrop ND-1000
Spectrophotometer (Nanodrop). Only RNA with an optical
density (OD) 260/280 ratio between 1.9 and 2.1 was used for
PCR analysis. RNA was stored at - 80C until further use.
Quantitative real-time reverse transcription–
polymerase chain reaction
qPCR was performed on the CFX96TM Real-Time PCR
(Biorad Laboratories, #185-5096). 200 ng total RNA with
oligo(dT) and random primers was reverse transcribed to
cDNA using iScriptTM (Biorad Laboratories, #170-8891) in a
total reaction volume of 20mL. A temperature program of 5-
min priming at 25C followed by the reverse transcription at
42C for 30min and the reverse transcription inactivation at
85C for 5min was run. After a final cool-down to 4C, the
cDNA was stored at - 80C for subsequent use. The oligo-
nucleotides (purchased from Microsynth AG) displayed in
Supplementary Table S1 (Supplementary Data are avail-
able online at www.liebertpub.com/tec) were reconstituted
at a concentration of 100 mM and stored at - 20C for further
use. All primers are designed over exon–exon junctions using
PrimerBlast (http://ncbi.nlm.nih.gov/tools/primer-blast/)
and the Real Time PCR Design Tool from Integrated DNA
Technologies (http://eu.idtdna.com/Scitools/Applications/
RealTimePCR/Default.aspx) to avoid the amplification of
genomic DNA. Only primer pairs with efficiency between
90% and 110% were used in this study. A final concentration
of 150 nM forward and reverse primer, respectively, was
used for each qPCR. The iQ SYBR Green System (Biorad
Laboratories, #170-8880) was used to perform the qPCR
amplification from the cDNA in a final volume of 20 mL with
5 mL of 1:5 diluted cDNA. The cycling conditions were as
follows: an initial 95C for 3min, followed by 40 cycles of
95C for 10 s and 60C for 30 s. Then, a melting curve was
constructed by heating from 65C to 95C in temperature
steps of 0.5C. A multivariable, nonlinear regression method
was used by CFX Manager Software (Version 2.0, Biorad
Laboratories) to determine the quantification cycle values
(termed Cq according to MIQE guidelines5).
Results were exported to Microsoft Excel for analysis.
Results are presented as mean values from triplicate
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FIG. 2. Gene expression profile of
key differentiation markers. Gene ex-
pression profile of donor 2 at passages
1 (triangle) and 4 (circle) during (A)
adipogenic, (B) chondrogenic, and (C)
osteogenic differentiation over 22 days.
RPL13a was used as a normalizer and
control culture day 2 as calibrator of all
data. RPL13a, ribosomal protein L13a;
aP2, fatty acid-binding protein 4;
PPARg, peroxisome proliferator-acti-
vated receptor gamma.
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measurements, and variances are calculated according to the
laws of uncertainty propagation.15
Expression of differentiation markers
All qPCR data differentiation markers were analyzed us-
ing the 2 -DDCq method16 (assuming that the amplification
efficiency equals 100%) and normalized against an RG. Day 2
of control culture was designated as the calibrator in each
experiment. Each gene was evaluated in independent PCR
runs, including the complete set of samples of one donor and
passage (i.e., donor 1, passage 1, and days 2, 9, 16, and 22 of
control and differentiation culture).
Immunofluorescent staining
For immunofluorescent staining, the cells were washed
twice with PBS without glucose (PBS w/o glucose; Gibco,
#18912-014), treated with 4% paraformaldehyde (Sigma,
#16005) plus 0.2% Triton-X for 8min, and then washed again
twice with PBS w/o glucose. Nonspecific binding of anti-
bodies was blocked with PBS w/o glucose-containing 5% goat
serum (Sigma, #G6767) and 1% fetal calf serum for 30min.
The osteogenic characterization was determined using the
bone-specific marker anti-collagen I (1:1000; Sigma, #C2456)
and goat a-mouse immunoglobulin G Alexa Fluor 546 (1:400;
Molecular Probes, #A11030). The antibody was diluted in
1.5% skim milk/PBS and incubated for 1 h at room tem-
perature (RT). The cell nuclei were stained with DAPI (4¢-
6-diamidino-2-phenylindole, 10mg/mL; Sigma, #D9542)
together with the secondary antibody.
Adipogenic differentiation was determined by Oil Red O
staining. Briefly, cells were fixed with 4% paraformaldehyde
(as described above) and washed twice with distilled water;
after one washing step with 60% isopropanol, the cells were
incubated in 60% isopropanol for 5min at RT. Further, the
cells were incubated in an Oil Red O working solution
(2mg/mL Oil Red O in isopropanol and double-distilled
water, ratio 3:2) for 10min at RT. Before fluorescence mi-
croscopy (Axio Imager.M1; Carl Zeiss AG) imaging was
performed, the cells were washed with distilled water till
optimal contrast of red-stained lipid droplets was achieved.
Histology
Cell pellets were fixed with 4% formalin, embedded in
paraffin, and sectioned at 2mm. Tissue sections were then
deparaffinized using xylene followed by a graded alcohol
series and stained with hematoxylin/eosin to identify his-
tologic features and Alcian blue/periodic acid Schiff (PAS)
for proteoglycan.
Evaluation of RGs
The expression stability of seven common RGs (18S,
ACTB, B2M, EF1a, GAPDH, RPL13a, and YWHAZ) was
analyzed based on four different parameters:
(1) Interquartile range (IQR) representing the distribution
of the Cq values. The IQR spans between the 75th and the
25th percentile of the boxplots delimiting with the whiskers,
the maximum and minimum values; with the horizontal line,
the median; and the outliers with a point, respectively.
(2) Variation between differentiation culture and control
culture ( p-value) established by an unpaired one-way t-test
with a 95% confidence level. The null hypothesis (differen-
tiation equals control culture) is rejected if the p-value < 0.05
showed statistically significant difference between control
and differentiation cultures.
(3) Average fold changes (AFC) calculated by subtracting
the mean Cq value for each time point in control or differ-
entiation culture from the mean Cq value corresponding to
the control culture at day 2. DCq is further transformed into
fold differences with the formula 2 -DCq.13,17
(4) Maximum fold change (MFC) calculated similarly to
the AFC though considering the maximum/minimum in-
stead of the mean Cq value.13,18
(1) and (2) were calculated of the entire dataset of Cq
values of three different donors at two different passages in
control as well as in differentiation culture. (3) and (4) were
calculated at each time point, using day 2 of control culture
Table 2. Summary of the Stability Parameters
Evaluated for all Seven Reference Genes
in Chondro-, Adipo-, and Osteogenic Differentiation
Differentiation Primer IQR p-value AFC MFC
Adipogenesis 18S 0.43 3.5E-01 1.60 1.92
EF1a 0.67 6.8E-01 1.39 1.48
RPL13a 0.52 7.0E-02 1.46 1.57
B2M 0.77 6.9E-15 1.85 2.08
ACTB 1.59 2.2E-16 7.12 8.35
GAPDH 0.95 3.9E-05 1.93 2.35
YWHAZ 1.01 2.2E-16 3.14 3.43
Chondrogenesis 18S 0.95 3.7E-02 1.61 1.90
EF1a 1.15 7.5E-01 4.20 5.72
RPL13a 0.35 2.2E-01 1.90 2.11
B2M 0.95 1.3E-14 3.21 3.54
ACTB 0.79 2.6E-01 1.80 2.61
GAPDH 1.82 9.7E-02 14.43 20.05
YWHAZ 0.43 4.2E-01 1.53 1.85
Osteogenesis 18S 1.17 5.2E-02 1.47 1.71
EF1a 0.75 2.1E-08 2.35 2.83
RPL13a 0.68 6.0E-02 1.65 1.83
B2M 0.74 4.6E-16 1.73 2.11
ACTB 0.91 2.6E-01 3.09 3.36
GAPDH 1.02 3.0E-16 2.33 2.72
YWHAZ 0.80 1.2E-06 2.65 3.01
All 18S 0.77 8.5E-01 < 2 < 2.2
EF1a 0.95 3.9E-03 > 2 > 2.2
RPL13a 0.59 5.6E-01 < 2 < 2.2
B2M 0.85 2.2E-16 > 2 > 2.2
ACTB 1.21 9.5E-13 > 2 > 2.2
GAPDH 1.43 3.6E-03 > 2 > 2.2
YWHAZ 0.78 2.2E-16 > 2 > 2.2
Coefficient of variation (%) calculated by the SD divided by the
mean, p-value of the t-test showing the variation between the ct
values of control and differentiation cultures, inter quartile range
(IQR), average fold change (AFC), and maximum fold change
(MFC). For AFC and MFC, the highest value of the whole dataset is
represented. The reference genes fulfilling the selection criteria (IQR
< 0.7, p-value > 0.05, AFC < 2, and MFC < 2.2) during adipo-,
chondro-, and osteogenesis are highlighted in gray. The analysis of
all quantification cycle values of adipo-, chondro-, and osteogenesis
together (labeled as all) resulted in only RPL13a fulfilling the criteria.
EF1a, eukaryotic translational elongation factor 1 alpha; B2M, b2-
microglobulin; ACTB, beta-actin; GAPDH, glyceraldehyde-3-phos-
phate dehydrogenase; YWHAZ, tyrosine 3-monooxygenase/trypto-
phan 5-monooxygenase activation protein, zeta polypeptide; SD,
standard deviation.
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FIG. 3. Distribution of Cq values. (A) Adipo-, (B) chondro-, (C) osteogenesis. Left, values of all donors/passages in control
and differentiation culture. Right, data split up into control (grey) and differentiation (black) cultures. (D) All lineages together.
(E) RPL13a values of freshly isolated (hBM-MSCs), commercial bone marrow- (Lonza MSCs) and placenta-derived MSCs
(hPD-MSCs) as well as HBCs and MG-63. Cq, quantification cycle values; EF1a, eukaryotic translational elongation factor
1 alpha; B2M, b2-microglobulin; ACTB, beta actin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; YWHAZ, tyrosine
3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide; hBM-MSCs, human bone marrow-
derived MSCs; hPD-MSCs, human placenta-derived MSCs; HBCs, human bone cells; MG-63, human osteosarcoma cell line.
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as calibrator. The obtained values of all time points and
conditions of the entire dataset are in the case of AFC aver-
aged, and for MFC, the highest one is represented in Table 2.
The calculation of AFC and MFC assumes a primer efficiency
of 100%. The perfect RG would show no variation in the Cq
value during the process of differentiation and would result
in AFC and MFC values equal to one, p-value > 0.05, and
IQR of zero. The statistical analysis was performed using R
Project for Statistical Computing software (http://r-pro-
ject.org/index.html).
In addition to the statistical evaluation of RG stability
using the above-described criteria, geNorm,11 Normfinder,19
and BestKeeper20 algorithms were applied. Cq values
were put into the data file of Normfinder and BestKeeper
software, whereas AFC values were used for geNorm
analysis.
Results
Multilineage differentiation potential
The MSC multilineage differentiation potential of all
donors was confirmed by qPCR (Fig. 2 and Table 1) as well
as immunofluorescent and histochemical stainings (Fig. 1).
Adipogenic differentiation is marked by the appearance of
oil droplets stained by Oil Red O on day 16 (Fig. 1A). The
adipogenic markers fatty acid-binding protein 4 (aP2) and
peroxisome proliferator-activated receptor gamma (PPARg)
were expressed significantly at day 22 in all donors and
were at passage 4, sometimes even more abundant than at
passage 1 (Table 1). Chondrogenic differentiation was vi-
sualized using Alcian blue/PAS staining, revealing a light-
blue color upon the appearance of proteoglycans starting
on day 16 (Fig. 1B). Aggrecan and collagen II, the chon-
drogenic marker genes, are upregulated in all donors
(Table 1). In the osteogenically differentiated samples, col-
lagen I staining increased during the entire 22-day culture
period (Fig. 1C), which goes in line with the qPCR data
(Fig. 2 and Table 1). Osteocalcin, a later marker of osteo-
genesis, was expressed around day 9 and steadily increased
thereafter. The qPCR data show that all three donors are
exhibiting a multilineage differentiation potential (Fig. 2)
with a certain interpatient variability typical for MSC
studies (Table 1). The MSC-proliferation medium, contain-
ing FGF-2 to preserve the stem cell character,21 was used as
the control condition for adipo- and osteogenesis, exhibiting
no Oil Red O or collagen I staining on day 21, respectively.
The appropriate control condition for chondrogenesis was
confirmed by the absence of Alcian blue staining in pellet
cultures after 14 days.
Evaluation of RG expression stability
Expansion and differentiation of hBM-MSCs. To study
the expression stability of the seven RGs selected (for over-
view, see Supplementary Table S1) during differentiation, we
analyzed several parameters summarized in Table 2. The
distribution of the Cq of all donors was graphically depicted
in boxplots (Fig. 3), which delimit the 25th and 75th per-
centile of the dataset also known as the IQR (Table 2). Fur-
ther, a t-test was performed to assess the change between
control and differentiation cultures represented as side-by-
side boxplots in Figure 3A–C (right). The resulting p-value
(Table 2) reflects the probability that the Cq values for dif-
ferentiated samples are statistically different compared to
control cultures. In addition, AFC and MFC13,17 were cal-
culated (Fig. 4). The selection criteria applied in this work are
IQR < 0.7, p-value > 0.05, AFC < 2 (Fig. 4), and MFC < 2.2.
On the basis of these criteria, 18S (IQR = 0.43, p-value = 0.35,
AFC= 1.6, and MFC = 1.92), EF1a (IQR = 0.67, p-value = 0.68,
AFC= 1.39, and MFC = 1.48), and RPL13a (IQR = 0.52, p-val-
ue= 0.07, AFC= 1.46, and MFC = 1.57) are possible RGs to
normalize adipogenic differentiation studies (Figs. 3A and
4A). For chondrogenesis (Figs. 3B and 4B), RPL13a (IQR =
0.35, p-value = 0.22, AFC= 1.9, and MFC = 2.11) as well as
YWHAZ (IQR = 0.43, p-value= 0.42, AFC= 1.53, and MFC =
1.85) fulfilled the selection criteria, whereas only RPL13a
(IQR = 0.68, p-value = 0.06, AFC = 1.65, and MFC = 1.83) was
concluded to be a stably expressed RG during osteogenic
differentiation (Figs. 3C and 4C). On the other hand, the two
most unstably expressed RGs were ACTB and GAPDH with
MFC reaching up to 8.35 (ACTB during adipogenesis) and
20.05 (GAPDH during chondrogenesis). This unstability was
confirmed in the analysis of all differentiation lineages to-
gether, resulting in the two highest IQRs for ACTB (1.21) and
GAPDH (1.43) (Fig. 3D and Table 2). Taken together, RPL13a
FIG. 4. Fold changes (2 -DCq) in RG expression. Average
(columns) and maximum fold change (error bars) of (A)
adipo-, (B) chondro-, and (C) osteogenesis on days 9, 15, and
22 in a differentiation (diff) and control medium of all donors
and passages. Control day 2 was used as calibrator. Black
line indicates the selection criteria of the average fold range
< 2. RG, reference gene.
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shows the lowest variability across donors, passage num-
bers, as well as differentiation conditions with an IQR of 0.59,
p-value of 0.56, and MFC smaller than 2. Based on these
results, we ranked the genes according to their IQR (the
lower, the more stable). This ranking represented in Table 3
places RPL13a in the first place for chondrogenesis and os-
teogenesis and on the second place for adipogenesis. The
algorithms of geNorm, NormFinder, and Bestkeeper all
support the first rank of RPL13a for the analysis of chon-
drogenic induction experiments, whereas for adipogenesis
and osteogenesis, always two out of three show RPL13a in
the first rank (Table 3).
MSCs of different sources and bone cells. Once RPL13a
was selected as the RG of choice for hBM-MSCs, we further
tested its expression stability on commercially available
hBM-MSCs (Lonza MSCs) as well as hPD-MSCs during
adipo-, chondro-, and osteogenesis. The differentiation ex-
periments using Lonza MSCs were performed with pur-
chased cells from one donor and the hPD-MSCs cells from
two donors. RPL13a showed a similar distribution for these
two MSCs (Fig. 3E) as it does for the freshly isolated
hBM-MSCs and is therefore considered stably expressed
throughout mesodermal differentiation of MSCs. In a sub-
sequent step, we analyzed the RPL13a stability in gene ex-
pression during osteogenic differentiation of bone cells.
Primary HBCs as well as the MG-63 (human osteosarcoma
cell line) were therefore induced over 7 days (time points
analyzed: day 1, 4, 7) in an induction medium. The HBCs
show a comparable Cq distribution to that of MSCs (Fig. 3E),
whereas MG-63 cells, the only nonprimary cells, are ex-
pressing RPL13a at a higher level. Although exhibiting
a lower Cq mean, the distribution is narrow, indicating
a high expression stability of RPL13a during osteogenic
differentiation.
Effect of RG expression stability on marker
gene expression
The effect of the RG variance on the expression pattern of
the adipo-, chondro-, and osteomarkers was analyzed (Fig.
5). For clarity, only the relative expression of the marker
genes from the donor 2 at passage 1 is shown using GAPDH,
RPL13a, and ACTB as RGs. The instability of ACTB during
adipogenesis leads to an increase of 281% of the relative
expression of aP2 at day 22 compared to RPL13a. GAPDH,
being less variable, only shows an error of 28% (Fig. 5A). The
expression of collagen II during the chondrogenic differen-
tiation process is affected by a smaller degree by ACTB
(40%), but more pronounced by GAPDH (222%) (Fig. 5B).
This increase would be even higher when relating to the
control cultures of the chondrogenic lineage (Fig. 4B). The
normalization of the osteogenic-specific genes shows a re-
sulting error in collagen I expression of 186% for ACTB and
55% for GAPDH (Fig. 5C).
Discussion
In the present study, we have established RPL13a, a
member of the L13 ribosomal protein family and a structural
component of the large 60S ribosomal subunit, as the RG of
choice for MSC studies. Among the seven RGs—18S,
GAPDH, RPL13a, ACTB, YWHAZ, EF1a, and B2M—RPL13a
Table 3. Reference Gene Ranking Based on geNorm, NormFinder, and Bestkeeper Algorithms
and Interquartile Range
Rank GeNorm NormFinder BestKeeper IQR rating
Adipogenesis
1 EF1a (0.19) GAPDH (0.40) 18S (0.25) 18S (0.43)
2 RPL13a (0.2) B2M (0.48) RPL13a (0.28) RPL13a (0.52)
3 18S (0.21) YWHAZ (0.5) EF1a (0.37) EF1a (0.67)
4 GAPDH (0.27) EF1a (0.58) B2M (0.38) B2M (0.77)
5 B2M (0.3) 18S (0.58) GAPDH (0.51) GAPDH (0.95)
6 YWHAZ (0.36) RPL13a (0.59) YWHAZ (0.58) YWHAZ (1.01)
7 ACTB (0.53) ACTB (1.87) ACTB (1.04) ACTB (1.59)
Chondrogenesis
1 RPL13a (0.14) RPL13a (0.36) RPL13a (0.28) RPL13a (0.35)
2 18S (0.15) 18S (0.44) YWHAZ (0.31) YWHAZ (0.43)
3 YWHAZ (0.16) EF1a (0.58) ACTB (0.42) ACTB (0.79)
4 ACTB (0.28) YWHAZ (0.60) 18S (0.5) B2M (0.95)
5 EF1a (0.37) ACTB (1.00) B2M (0.68) 18S (0.95)
6 B2M (0.51) B2M (1.24) EF1a (0.68) EF1a (1.15)
7 GAPDH (0.70) GAPDH (2.54) GAPDH (1.09) GAPDH (1.82)
Osteogenesis
1 B2M (0.18) RPL13a (0.23) RPL13a (0.35) RPL13a (0.68)
2 EF1a (0.20) 18S (0.25) B2M (0.36) B2M (0.74)
3 GAPDH (0.20) B2M (0.26) EF1a (0.43) EF1a (0.75)
4 18S (0.24) EF1a (0.35) YWHAZ (0.46) YWHAZ (0.80)
5 RPL13a (0.27) YWHAZ (0.35) ACTB (0.53) ACTB (0.91)
6 YWHAZ (0.32) GAPDH (0.39) 18S (0.59) GAPDH (1.02)
7 ACTB (0.38) ACTB (0.45) GAPDH (0.6) 18S (1.17)
Rating based on different algorithms yielding expression stability values (shown in parenthesis). Algorithms used: geNorm (M value),
NormFinder, BestKeeper (SD[GCP]), and IQR rating. Ranking of RPL13a highlighted in gray.
SD[GCP], standard deviation of crossing point.
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showed the lowest expression variability throughout adipo-
genic, chondrogenic, and osteogenic differentiation of MSCs.
We have studied the stability in gene expression of the RGs
of three different donors at passages 1 and 4, proving that
RPL13a expression is stable not only during differentiation
but also during expansion to higher passages. This result is
confirmed by at least two out of three algorithms (geNorm,
NormFinder, and BestKeeper) known for the gene expres-
sion stability analysis. The discrepancy in the resulting sta-
bility ranking shows the difficulty of the RG stability
analysis, which is based on different arbitrarily chosen pa-
rameters. The majority of three out of four analysis methods
supporting RPL13a as the RG of choice is striking evidence
for its stability.
Next to freshly isolated hBM-MSCs, we applied RPL13a to
studies with commercially available and hPD-MSCs, where
its suitability for comparison studies between different MSCs
was confirmed. These findings are in agreement with several
studies on qPCR normalization. de Jonge et al.18 performed a
meta-analysis on 13,629 human gene array samples (in-
cluding stem cells) and identified RPL13a as one of the top 15
candidate RGs. The ranking based on the coefficient of var-
iation (CV) placed ACTB on position 57 and GAPDH on 139.
Vandesompele et al.11 studied different human tissues and
cells (including bone marrow) and concluded that RPL13a
and Ubiquitin C are the RGs with the smallest variation in
bone marrow samples. These two publications, studying the
stability of RGs in a wide variety of tissues, are lacking the
analysis of their variance during differentiation events. The
work of Curtis et al.12 focused on endothelial differentiation
of bone marrow-derived MSCs as well as their expansion
under different conditions. They have shown EF1a and
RPL13a expression to be stable under all studied experimental
conditions, but missing the differentiation into the common
mesodermal lineages. Quiroz et al.13 demonstrated the stabil-
ity of RPL13a expression for osteogenic differentiation of bone
marrow-derived MSCs, applying the selection criteria of AFC
andMFC < 2. Their study was performed using cells from one
donor at passage 5, thereby neglecting the interpatient vari-
ability. We decided, in the present work, to use cells from
three patients, to address this variability. Our results show
that the gene expression stability of RPL13a in the osteo-
genically induced cultures fulfills the criteria proposed by
Quiroz et al.,13 including not one, but three donors at different
passages. Osteogenesis though showed to be the mesodermal
differentiation lineage that was the least affected by changes
resulting from RG expression instability. Taking adipogenesis
and chondrogenesis in consideration as well, the selection
criteria had to be slightly alleviated to AFC < 2 and MFC
< 2.2. Additionally, our data confirm the use of RPL13a as an
RG in bone research, showing its stability not only under
osteogenic differentiation of MSCs but also of MG-63 and
primary bone cells. The higher abundance of RPL13a in the
osteosarcoma cell line MG-63 might be related to their tumor-
related origin as previously described for immortalization
processes known to affect cellular processes.23,24
GAPDH and ACTB, the two most widely used RGs in
MSC studies,12,25 showed the highest expression variability
of all seven RGs analyzed in bone marrow-derived MSCs.
GAPDH has been shown to play a role in many cellular
processes such as nuclear RNA export, DNA replication,
DNA repair, exocytotic membrane fusion, cytoskeletal or-
ganization, and phosphotransferase activity;26 therefore, its
mRNA level is prone to be affected by events such as dif-
ferentiation. The expression level of ACTB, a structural
protein associated with cell shape and motility, is expected to
be altered during adipo-, chondro-, and osteogenesis, the
three processes involving a major change in cell morpholo-
gy.27–30 The use of ribosomal RNA genes such as 18S, on the
other hand, is not only problematic due to their proven in-
stability (see Table 2)9,31,32 but also due to their high abun-
dance and the different transcription mechanism that,
compared to mRNA, is not carried out by RNA polymerase
II, but RNA polymerase I.31,33 We therefore highly recom-
mend abandoning the normalization based on these RGs in
the field of human MSC research.
The expression variability of RGs used in the MSC com-
munity hinders a conclusive comparison between different
studies and therefore puts their value into question. Our
work showing the instability in gene expression of com-
monly used RGs under expansion, adipo-, chondro-, and
osteogenic differentiation as well as between different MSCs
further demonstrates the necessity of establishing a common
RG to be used by all investigators working on MSCs. We
propose the use of RPL13a as a single RG instead of the
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FIG. 5. Effect of RG stability on marker gene expression.
Relative gene expression of (A) aP2 during adipogenic, (B)
collagen II during chondrogenic, and (C) collagen I during
osteogenic differentiation normalized by GAPDH (white
triangle), RPL13a (black circle), and ACTB (white square).
Data of donor 2 passage 1 were represented. Control culture
day 2 was used as calibrator.
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multiple-RG approach proposed by others,11 as the stability
of RPL13a is sufficiently high.
Acknowledgments
This work was supported by the Swiss National Science
Foundation (Grant CR23I2_130678) and the European Union
Seventh Framework Program (FP7/2007–2013) under the
grant agreement no. NMP4-SL-2009-229292 (Find&Bind).
The bone marrow samples employed in this work were
kindly provided by the Clinic of Orthopedic Surgery, Kan-
tonsspital St. Gallen, Switzerland, and BMP-2 was provided
by F. Weber, University Hospital Zu¨rich, Switzerland.
Disclosure Statement
No competing financial interests exist.
References
1. Tuan, R.S., Boland, G., and Tuli, R. Adult mesenchymal stem
cells and cell-based tissue engineering. Arthritis Res Ther 5,
32, 2003.
2. Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K.,
Douglas, R., Mosca, J.D., et al.Multilineage potential of adult
human mesenchymal stem cells. Science 284, 143, 1999.
3. Jiang, Y., Jahagirdar, B.N., Reinhardt, R.L., Schwartz, R.E.,
Keene, C.D., Ortiz-Gonzalez, X.R., et al. Pluripotency of
mesenchymal stem cells derived from adult marrow. Nature
418, 41, 2002.
4. Caplan, A.I. Adult mesenchymal stem cells for tissue engi-
neering versus regenerative medicine. J Cell Physiol 213,
341, 2007.
5. Bustin, S.A., Benes, V., Garson, J.A., Hellemans, J., Huggett,
J., Kubista, M., et al. The MIQE guidelines: minimum infor-
mation for publication of quantitative real-time PCR exper-
iments. Clin Chem 55, 611, 2009.
6. Wong, M.L., and Medrano, J.F. Real-time PCR for mRNA
quantitation. Biotechniques 39, 75, 2005.
7. Stu¨rzenbaum, S.R., and Kille, P. Control genes in quantita-
tive molecular biological techniques: the variability of in-
variance. Comp Biochem Physiol Part B 130, 281, 2001.
8. Bustin, S.A. Quantification of mRNA using real-time reverse
transcription PCR (RT-PCR): trends and problems. J Mol
Endocrinol 29, 23, 2002.
9. Huggett, J., Dheda, K., Bustin, S., and Zumla, A. Real-time
RT-PCR normalisation; strategies and considerations. Genes
Immun 6, 279, 2005.
10. Dheda, K., Chang, J.S., Kim, L.U., Bustin, S.A., Johnson,
M.A., Rook, G.A.W., et al. The implications of using an in-
appropriate reference gene for real-time reverse transcrip-
tion PCR data normalization. Anal Biochem 344, 141, 2005.
11. Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van
Roy, N., De Paepe, A., et al. Accurate normalization of real-
time quantitative RT-PCR data by geometric averaging of
multiple internal control genes. Genome Biol 3, RE-
SEARCH0034, 2002.
12. Curtis, K.M., Schiller, P.C., Gomez, L.A., Rios, C., Garbayo,
E., Raval, A.P., et al. EF1 alpha and RPL13a represent nor-
malization genes suitable for RT-qPCR analysis of bone
marrow derived mesenchymal stem cells. BMC Mol Biol 11,
61, 2010.
13. Quiroz, F.G., Posada, O.M., Gallego-Perez, D., Higuita-
Castro, N., Sarassa, C., Hansford, D.J., et al. Housekeeping
gene stability influences the quantification of osteogenic
markers during stem cell differentiation to the osteogenic
lineage. Cytotechnology 62, 109, 2010.
14. Semenov, O.V., Koestenbauer, S., Riegel, M., Zech, N.,
Zimmermann, R., Zisch, A.H., et al. Multipotent mesenchy-
mal stem cells from human placenta: critical parameters for
isolation and maintenance of stemness after isolation. Am J
Obstet Gynecol 202, 193.e1, 2010.
15. JCGM. 100 Evaluation of Measurement Data—Guide to the
Expression of Uncertainty Measurement (GUM), 2008. www
.iso.org/sites/JCGM/GUM-introduction.htm
16. Livak, K.J., and Schmittgen, T.D. Analysis of relative gene
expression data using real-time quantitative PCR and the 2(-
Delta Delta C(T)) method. Methods 25, 402, 2001.
17. Dheda, K., Huggett, J.F., Bustin, S.A., Johnson, M.A., Rook,
G., and Zumla, A. Validation of housekeeping genes for
normalizing RNA expression in real-time PCR. Biotechni-
ques 37, 112, 2004.
18. de Jonge, H.J., Fehrmann, R.S., de Bont, E.S., Hofstra, R.M.,
Gerbens, F., Kamps, W.A., et al. Evidence based selection of
housekeeping genes. PLoS One 2, e898, 2007.
19. Andersen, C.L., Jensen, J.L., and Orntoft, T.F. Normalization
of real-time quantitative reverse transcription-PCR data: a
model-based variance estimation approach to identify genes
suited for normalization, applied to bladder and colon can-
cer data sets. Cancer Res 64, 5245, 2004.
20. Pfaffl, M.W., Tichopad, A., Prgomet, C., and Neuvians, T.P.
Determination of stable housekeeping genes, differentially
regulated target genes and sample integrity: BestKeeper—
Excel-based tool using pair-wise correlations. Biotechnol
Lett 26, 509, 2004.
21. Ahn, H.J., Lee, W.J., Kwack, K., and Do Kwon, Y. FGF2
stimulates the proliferation of human mesenchymal stem
cells through the transient activation of JNK signaling. FEBS
Lett 583, 2922, 2009.
22. Pombo-Suarez, M., Calaza, M., Gomez-Reino, J.J., and
Gonzalez, A. Reference genes for normalization of gene ex-
pression studies in human osteoarthritic articular cartilage.
BMC Mol Biol 9, 17, 2008.
23. Kartsogiannis, V., and Ng, K.W. Cell lines and primary cell
cultures in the study of bone cell biology. Mol Cell En-
docrinol 228, 79, 2004.
24. Pan, C.P., Kumar, C., Bohl, S., Klingmueller, U., and Mann,
M. Comparative Proteomic phenotyping of cell lines and
primary cells to assess preservation of cell type-specific
functions. Mol Cell Proteomics 8, 443, 2009.
25. Suzuki, T., Higgins, P.J., and Crawford, D.R. Control selec-
tion for RNA quantitation. Biotechniques 29, 332, 2000.
26. Sirover, M.A. New insights into an old protein: the
functional diversity of mammalian glyceraldehyde-3-
phosphate dehydrogenase. Biochim Biophys Acta 1432,
159, 1999.
27. Nurminskaya, M., Nurminsky, D., Magee, C., and Faver-
man, L. Regulation of chondrocyte differentiation by actin-
severing protein adseverin. Dev Biol 302, 427, 2007.
28. Rodriguez, J.P., Gonzalez, M., Rios, S., and Cambiazo, V.
Cytoskeletal organization of human mesenchymal stem cells
(MSC) changes during their osteogenic differentiation. J Cell
Biochem 93, 721, 2004.
29. McBeath, R., Pirone, D.M., Nelson, C.M., Bhadriraju, K., and
Chen, C.S. Cell shape, cytoskeletal tension, and RhoA regu-
late stem cell lineage commitment. Develop Cell 6, 483, 2004.
30. Born, A.K., Rottmar, M., Lischer, S., Pleskova, M., Bruinink,
A., and Maniura-Weber, K. Correlating cell architecture with
770 STUDER ET AL.
osteogenesis: first steps towards live single cell monitoring.
Eur Cell Mater 18, 49, 2009.
31. Solanas, M., Moral, R., and Escrich, E. Unsuitability of using
ribosomal RNA as loading control for Northern blot analy-
ses related to the imbalance between messenger and ribo-
somal RNA content in rat mammary tumors. Anal Biochem
288, 99, 2001.
32. Tanaka, S., Furukawa, T., and Plotkin, S.A. Human cyto-
megalovirus stimulates host-cell RNA-synthesis. J Virol 15,
297, 1975.
33. Radonic, A., Thulke, S., Mackay, I.M., Landt, O., Siegert, W.,
and Nitsche, A. Guideline to reference gene selection for
quantitative real-time PCR. Biochem Biophys Res Commun
313, 856, 2004.
Address correspondence to:
Katharina Maniura-Weber, Ph.D.
Laboratory for Materials-Biology Interactions
Empa, Swiss Federal Laboratories for
Materials Testing and Research
Lerchenfeldstrasse 5
St. Gallen 9014
Switzerland
E-mail: katharina.maniura@empa.ch
Received: February 10, 2012
Accepted: April 4, 2012
Online Publication Date: May 31, 2012
RPL13A AS A REFERENCE GENE FOR MSC RESEARCH 771
